Medroxyprogesterone Acetate and Progesterone, Used Short Term, Do not Adversely Affect Forearm Reactive Hyperemia in Postmenopausal Women on Estradiol Therapy

authors:

avatar MM Cho 1 , * , avatar HN Hodis 2 , avatar WJ Mack 2 , avatar S Roy 2 , avatar RJ Paulson 2 , avatar Y Li 2 , avatar FZ Stanczyk 2

Department of Obstetrics, Gynecology, and Womens Health, UMDNJ-New Jersey Medical School, chomm@umdnj.edu, NJ
Departments of Medicine and Preventive Medicine, Atherosclerosis Research Unit, USA
International Journal of Endocrinology and Metabolism: Vol.6, issue 2; 63-69
article type: Original Article
received: June 30, 2007
accepted: January 2, 2008

how to cite: Cho M, Hodis H, Mack W, Roy S, Paulson R, et al. Medroxyprogesterone Acetate and Progesterone, Used Short Term, Do not Adversely Affect Forearm Reactive Hyperemia in Postmenopausal Women on Estradiol Therapy. Int J Endocrinol Metab. 2008;6(2): 63-69. 

Abstract

This study aimed at investigating whet-her oral medroxyprogesterone acetate (MPA) or micronized progesterone (P) combined with micronized estradiol (E2) adversely affect endothelial function in postmenopausal women. Materials and Methods: Randomized, double-blind, crossover trial of MPA or micronized P with oral E2 treatment in menopausal women. Result: Flow-mediated, endothelium-dependent vasodilation of the brachial artery was not sig-nificantly affected by short-term administration of E2 alone or E2 combined with cyclic MPA, or E2 combined with cyclic P. Conclusion: Short-term oral E2 treatment of postmenopausal women alone or with cyclic oral MPA or oral P did not affect flow-mediated en-dothelium-dependent vasodilation.

Full Text

Full text is available in PDF